Information
-
Trademark
-
97541653
-
Serial Number
97541653
-
Registration Number
7159329
-
International Classifications
-
Filing Date
August 09, 2022
2 years ago
-
Registration Date
September 05, 2023
a year ago
-
Transaction Date
June 25, 2024
6 months ago
-
Status Date
September 05, 2023
a year ago
-
Published for Opposition Date
February 07, 2023
a year ago
-
Location Date
August 01, 2023
a year ago
-
First Use Anywhere Date
December 13, 2022
2 years ago
-
First Use In Commerce Date
December 13, 2022
2 years ago
-
Status Code
700
-
Current Location
PUBLICATION AND ISSUE SECTION
Employee Name
SINGLETON, RUDY RENWIC
-
Attorney Docket Number
00163766-US
Attorney Name
Marilyn F. Kelly
Law Office Assigned Location Code
L20
-
Owners
Mark Drawing Code
5
Mark Identification
KRAZATI
Case File Statements
- DM0000: The mark consists of the stylized term "KRAZATI". The black background in this mark drawing represents background and/or transparent areas only and is not claimed as a feature of this mark.
- GS0051: pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors
- CC0000: Color is not claimed as a feature of the mark.
- GS0421: research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
Case File Event Statements
-
8/29/2022 - 2 years ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
8/12/2022 - 2 years ago
1 - NEW APPLICATION ENTERED
Type: NWAP
-
9/28/2022 - 2 years ago
3 - ASSIGNED TO EXAMINER
Type: DOCK
-
9/29/2022 - 2 years ago
4 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
9/29/2022 - 2 years ago
5 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
9/29/2022 - 2 years ago
6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
12/30/2022 - a year ago
7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
12/30/2022 - a year ago
8 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
12/31/2022 - a year ago
9 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
12/31/2022 - a year ago
10 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
1/18/2023 - a year ago
11 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
2/7/2023 - a year ago
12 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
2/7/2023 - a year ago
13 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
-
4/4/2023 - a year ago
14 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Type: NOAM
-
4/19/2023 - a year ago
15 - TEAS STATEMENT OF USE RECEIVED
Type: EISU
-
4/19/2023 - a year ago
17 - USE AMENDMENT FILED
Type: IUAF
-
5/8/2023 - a year ago
16 - CASE ASSIGNED TO INTENT TO USE PARALEGAL
Type: AITU
-
5/9/2023 - a year ago
18 - STATEMENT OF USE PROCESSING COMPLETE
Type: SUPC
-
8/1/2023 - a year ago
19 - ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Type: CNPR
-
8/2/2023 - a year ago
20 - NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Type: SUNA
-
9/5/2023 - a year ago
22 - NOTICE OF REGISTRATION CONFIRMATION EMAILED
Type: NRCC
-
9/5/2023 - a year ago
21 - REGISTERED-PRINCIPAL REGISTER
Type: R.PR
-
6/25/2024 - 6 months ago
25 - TEAS CHANGE OF CORRESPONDENCE RECEIVED
Type: TCCA
-
6/25/2024 - 6 months ago
23 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Type: REAP
-
6/25/2024 - 6 months ago
24 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Type: ARAA